AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
September 4, 2019
· 4 min read